Bristol Myers Squibb’s Alzheimer’s Drug, BMS-986446, Granted FDA Fast Track Status

Bristol-Myers Squibb Company (NYSE:BMY) is one of the cheap stocks to buy for the next 5 years. On October 2, Bristol Myers Squibb announced a development in its Alzheimer’s program: its experimental drug, BMS-986446, received Fast Track designation from the US FDA. The designation expedites the review process for the drug, which is currently in Phase 2 testing for patients in the early stages of Alzheimer’s disease. In preclinical studies, the drug demonstrated a sharp reduction in tau uptake and spread, ...